Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1426 AL 1440

Taking sides: is handedness involved in motor asymmetry of Parkinson's disease?

Melamed E, Poewe W.

Mov Disord. 2012 Feb;27(2):171-3. doi: 10.1002/mds.24048. Epub 2012 Jan 5.

Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?

Pignatti R, Brioschi A, Mauro A, Zamarian L, Wenter J, Semenza C.

Neurocase. 2012;18(6):503-13. doi: 10.1080/13554794.2011.633529. Epub 2012 Jan 6.

What predicts cognitive decline in de novo Parkinson's disease?

Arnaldi D, Campus C, Ferrara M, Famà F, Picco A, De Carli F, Accardo J, Brugnolo A, Sambuceti G, Morbelli S, Nobili F.

Neurobiol Aging. 2012 Jun;33(6):1127.e11-20. doi: 10.1016/j.neurobiolaging.2011.11.028. Epub 2012 Jan 5.

Visual hallucinations in the differential diagnosis of parkinsonism

Bertram K, Williams DR.

J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):448-52. doi: 10.1136/jnnp-2011-300980. Epub 2012 Jan 6.

Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests

Iodice V, Lipp A, Ahlskog JE, Sandroni P, Fealey RD, Parisi JE, Matsumoto JY, Benarroch EE, Kimpinski K, Singer W, Gehrking TL, Gehrking JA, Sletten DM, Schmeichel AM, Bower JH, Gilman S, Figueroa J, Low PA.

J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):453-9. doi: 10.1136/jnnp-2011-301068. Epub 2012 Jan 6.

Potential role of green tea catechins in various disease therapies: progress and promise

Mak JC.

Clin Exp Pharmacol Physiol. 2012 Mar;39(3):265-73. doi: 10.1111/j.1440-1681.2012.05673.x.

Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease

Panaro MA, Cianciulli A.

Curr Pharm Des. 2012;18(2):200-8. doi: 10.2174/138161212799040574.

Targeting mitochondria for neuroprotection in Parkinson's disease

Schapira AH.

Antioxid Redox Signal. 2012 May 1;16(9):965-73. doi: 10.1089/ars.2011.4419.

Development of Parkinson's disease in patients with Narcolepsy

Christine CW, Marks WJ Jr, Ostrem JL.

J Neural Transm (Vienna). 2012 Jun;119(6):697-9. doi: 10.1007/s00702-011-0761-z. Epub 2012 Jan 10.

REM sleep behavior disorder in Japanese patients with Parkinson's disease: a multicenter study using the REM sleep behavior disorder screening questionnaire

Nihei Y, Takahashi K, Koto A, Mihara B, Morita Y, Isozumi K, Ohta K, Muramatsu K, Gotoh J, Yamaguchi K, Tomita Y, Sato H, Seki M, Iwasawa S, Suzuki N.

J Neurol. 2012 Aug;259(8):1606-12. doi: 10.1007/s00415-011-6386-1. Epub 2012 Jan 10.

Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool

Broen MP, Braaksma MM, Patijn J, Weber WE.

Mov Disord. 2012 Apr;27(4):480-4. doi: 10.1002/mds.24054. Epub 2012 Jan 9.

SIRT1: new avenues of discovery for disorders of oxidative stress

Chong ZZ, Shang YC, Wang S, Maiese K.

Expert Opin Ther Targets. 2012 Feb;16(2):167-78. doi: 10.1517/14728222.2012.648926. Epub 2012 Jan 10.

New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

Blandini F, Armentero MT.

Expert Opin Investig Drugs. 2012 Feb;21(2):153-68. doi: 10.1517/13543784.2012.651457. Epub 2012 Jan 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias